| Literature DB >> 19759830 |
Laura Heath1, Alan Fox, Jan McClure, Kurt Diem, Angélique B van 't Wout, Hong Zhao, David R Park, Jeffrey T Schouten, Homer L Twigg, Lawrence Corey, James I Mullins, John E Mittler.
Abstract
BACKGROUND: HIV-1 is frequently detected in the lungs of infected individuals and is likely important in the development of pulmonary opportunistic infections. The unique environment of the lung, rich in alveolar macrophages and with specialized local immune responses, may contribute to differential evolution or selection of HIV-1. METHODOLOGY ANDEntities:
Mesh:
Substances:
Year: 2009 PMID: 19759830 PMCID: PMC2736399 DOI: 10.1371/journal.pone.0006949
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical information of study subjects at time of sampling.
| Subject | HIV-RNA | CD4 | Time Infected | Therapy at first sample | Smoker | AM Enrichment Procedures | % AM | # IS/BAL sequences | # PL sequences | # PBM sequences | # PBL sequences | # PBMC sequences |
| IS-8247 | <50 | 517 | >8 yr | R, N, S, Z (>5 yr) | N | 7 | 7 | 12 | 14 | |||
| IS-8835 | 399,060 | 7 | >8 yr | None | N | 12 | 13 | 7 | 13 | |||
| IS-8837 | 64,820 | 297 | >1 yr | None | N | 13 | 14 | 7 | 11 | |||
| IS-8838 | 3,610 | NA | >8 yr | None | Y | 13 | 11 | 13 | ||||
| IS-8840 | 3,500 | 1044 | >8 yr | None | Y | 13 | 11 | 10 | 9 | |||
| IS-8886 | <50 | 737 | >9 yr | N, Z, L (>4 yr) | Y | 10 | 4 | 14 | 14 | |||
| IS-8948 | 56,270 | 764 | >3 yr | None | Y | 17 | 13 | 18 | ||||
| IS-8992 | 15,600 | NA | >16 yr | None | Y | 8 | 18 | 11 | ||||
| IS-9000 | 52 | 301 | ∼2.1 yr | E, T, Z, L (4 mo) | NA | 8 | 13 | 8 | ||||
| IU-BAL1 | 53,533 | 361 | NA | None | N | Not AM enriched | 41 | 25 BALC | 34 | |||
| IU-BAL2 | 272,961 | 313 | NA | None | NA | Not AM enriched | 10 | 24 BALC | 32 | |||
| IU-BAL3 | 31,844 | 430 | NA | None | NA | Not AM enriched | 67 | 24 BALC | 33 | |||
| IU-BAL4 | 23,794 | NA | NA | None | Y | Not AM enriched | 92 | 25 BALC | 46 | |||
| UW-BAL5 | 141,321 | 270 | ∼0.9 yr | None | N | LSM and CD3-depleted | ≥84 | 18 BALC*, 14 BALF | 17 | 7 | 13 | |
| UW-BAL6 | 14,642 | 445 | ∼5 yr | None | N | LSM and CD3-depleted | ≥87 | 22 | 16 | 12 | ||
| UW-BAL8 | 72,691 | 426 | ∼10 yr | None | Y | LSM and CD3-depleted | ≥91 | 17 BALC*, 8 BALF | 18 | 6 | 9 | |
| UW-BAL9 | 40,304 | 253 | ∼20 yr | None | Y | LSM and CD3-depleted | ≥99 | 8 | 8 | 10 | 14 | |
| UW-BAL10 | 8,001 | 171 | ∼1.5 yr | None | N | Percoll gradient prior to CD3 depletion, plus adherence | ≥99 | 14 BALC**, 14 BALC*** | 11 | 16 |
IS indicates subjects from the induced sputum cohort, IU-BAL indicates subjects from the Indiana University cohort, and UW-BAL indicates subjects from the University of Washington cohort.
In cases where exact time was not known, patient was asked to provide an estimate.
R = ritonavir, N = nevirapine, S = saquinavir, Z = zidovudine, L = lamivudine, E = efavirenz, T = tenofovir.
Viral load dipped to 400 copies during brief period of HAART 5 months before BAL.
Patient had history of HAART reducing VL to undetectable levels in 1997, 2000, and 2001.
Figure 1HIV-1 co-receptor usage predictions.
X4 viruses were predicted in (A) four IS subjects and (B) on IU subject (IU-BAL4) in multiple timepoints via the WebPSSM. There were no significant differences in frequency of X4 detection between tissues within any subject (Fisher's Exact Test).
Figure 2Phylogenetic trees of IS subjects.
All trees are maximum likelihood trees calculated under the best-estimated model as determined by ModelTest.
Figure 3Phylogenetic trees of BAL subjects.
All trees are maximum likelihood trees calculated under the best-estimated model as determined by ModelTest. (A) IU-BAL (Indiana University bronchoalveolar lavage) subjects; (B) UW-BAL (University of Washington bronchoalveolar lavage) subjects. ** and ***: alternative methods of AM enrichment in subject UW-BAL10, see methods.
Results of compartmentalization tests.
| Subject | Tissues from which we obtained sequences | Lung vs. blood tissue pairs in which compartmentalization | Blood vs. blood tissue pairs in which compartmentalization was detected | SM |
|
|
| AI |
| IS-8247 | IS, PBL, PBM, PL | Lung vs PL | – |
|
|
| ||
| IS-8835 | IS, PBL, PBM, PL | – | – |
| ||||
| IS-8837 | IS, PBL, PBM, PL | Lung vs PBL |
|
|
|
| ||
| Lung vs PL |
|
|
| |||||
| PBL vs PL |
|
|
|
| ||||
| IS-8838 | IS, PBL, PL | Lung vs PBL | – |
|
|
| ||
| IS-8840 | IS, PBL, PBM, PL | Lung vs PL |
|
|
|
| ||
| PBL vs PL |
|
|
| |||||
| PBM vs PL |
|
|
|
| ||||
| IS-8886 | IS, PBL, PBM, PL | – | – |
| ||||
| IS-8948 | IS, PBMC, PL | – | – |
| ||||
| IS-8992 | IS, PBMC, PL | Lung vs PL |
|
|
|
| ||
| PBMC vs PL |
|
|
|
| ||||
| IS-9000 | IS, PBM, PL | Lung vs PBM | – |
|
|
| ||
| IU-BAL1 | BALC | – | – |
| ||||
| IU-BAL2 | BALC | – | – |
| ||||
| IU-BAL3 | BALC | – | – |
| ||||
| IU-BAL4 | BALC | Lung vs PBMC | – |
|
|
| ||
| UW-BAL5 | BALC | – | – |
| ||||
| UW-BAL6 | BALC | Lung vs PBL | – |
|
|
|
|
|
| Lung vs PL |
|
|
|
|
| |||
| UW-BAL8 | BALC | Lung (BALC |
|
|
|
| ||
| PBM vs PL |
|
|
| |||||
| UW-BAL9 | BALC | Lung vs PBL |
|
|
|
| ||
| PBL vs PL |
|
|
|
| ||||
| PBM vs PL |
|
|
| |||||
| UW-BAL10 | BALC | – | – |
|
Only tissue pairs that were designated as compartmentalized with respect to one another (defined as having significant results in 3/5 tests) are listed.
Compartmentalization was designated when significance was detected in at least 3 of the 5 statistical tests.
BALF: HIV-RNA from bronchoalveolar lavage fluid.
BAL cells not enriched from AM (BALC in Table 1).
BAL cells enriched by LSM and CD3-depleted (BALC* in Table 1).
BAL cells fractionated on 46% Percoll gradients prior to CD3-depletion (BALC** in Table 1).
BAL cells treated as in 5 above, but further enriched for AM by adherence (BALC*** in Table 1).
p-value = 0.01–0.05.
p-value = 0.001–0.009.
p-value <0.001 (blank = p-value >0.05).
NS Data not shown, no tissue pair met the criteria for compartmentalization.
Figure 4Divergence from MRCA.
Distances were calculated under maximum likelihood parameters established under ModelTest. Pair comparisons were made using the Wilcoxon Rank Sums test. (A) IS subjects; (B) IU-BAL subjects; (C) UW-BAL subjects. For pair comparisons: *p-value = 0.01–0.05; **p-value = 0.001–0.009; ***p-value<0.001.